Capecitabine
نویسندگان
چکیده
منابع مشابه
Capecitabine-Induced Coronary Vasospasm
Capecitabine, an oral prodrug of 5-fluorouracil (5-FU), is approved for early-stage and advanced colorectal cancer and metastatic breast cancer. Cardiotoxicity of 5-FU is well described in the literature. However, cardiac adverse effects of capecitabine are poorly described. We report a case of coronary vasospasm induced by capecitabine. A 41-year-old female with metastatic breast cancer presen...
متن کاملUnanticipated toxicity to capecitabine.
A 63-year-old African American woman, L.L., was diagnosed with hormone-negative, HER2-negative, stage IIIa breast cancer 18 months ago. Following a left modified radical mastectomy with immediate reconstruction, L.L. was treated with dose-dense adriamycincyclophosphamide followed by paclitaxel. Follow-up visits were uneventful until a month ago, when she reported persistent right-upper quadrant...
متن کاملTravel warning with capecitabine.
Capecitabine has been shown to have single-agent activity in recurrent and metastatic nasopharyngeal carcinoma. Significantly better survival was observed in patients who had severe hand–foot syndrome treated with capecitabine [1]. Modifying the dosing schedule can be used to manage hand– foot syndrome [2]. USA international airports have been fingerprinting foreign visitors for many years. Eac...
متن کاملCapecitabine in colorectal cancer.
Capecitabine (Xeloda) is the first orally available fluoropyrimidine approved for use in patients with cancer. It was initially approved for use in metastatic breast cancer, but significant data also support its use in the management of metastatic colorectal cancer. Capecitabine relies on a series of metabolic steps, the last of which occurs primarily within cancer cells. This results in select...
متن کاملCapecitabine in colorectal cancer
Background to colorectal cancer Colorectal cancer is one of the three most commonly diagnosed cancers in the UK and western countries. A total of 13% of all cancers and 11% of all cancer-related deaths in the UK are attributable to colorectal cancer. This constitutes approximately 36,000 new patients and 16,000 deaths per year [1]. Systemic treatment options for patients with colorectal cancer ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Reactions Weekly
سال: 2021
ISSN: ['1179-2051', '0114-9954']
DOI: https://doi.org/10.1007/s40278-021-94974-1